Most breast cancer cases occurred within 12 months of treatment in women who experienced greater weight loss, which could have facilitated higher mammogram uptake/accuracy and thus, earlier detection of breast masses.24 Also of note, early pre-clinical data suggested some potential increase in the risk of rare cancers including thyroid C-cell tumors among users of GLP-1RA; however, since their approval, clinical trials have found no evidence of an increased risk of any cancer with GLP-1 RA therapy.25 The gene discussed is GLP1R; the disease is cancer.